Login
$CAPR
$8.20 -$0.10 (1.22%) After hours

$CAPR SEC Filings

Filed On Filing
13 Nov 2026 SCHEDULE 13G/A
10 Nov 2026 10-Q
10 Nov 2026 8-K: Results of Operations and Financial Condition

Deramiocel Biologics License Application (BLA) for Duchenne muscular dystrophy (DMD) under FDA review; PDUFA target action date of November 22, 2026

14 Oct 2026 SCHEDULE 13G/A
14 Sep 2026 SCHEDULE 13G
24 Aug 2026 8-K: Other Events

– New PDUFA target action date of November 22, 2026 follows submission of additional Phase 3 HOPE-3 data and analyses supporting a refined proposed indication –

19 Aug 2026 SCHEDULE 13G
14 Aug 2026 10-Q
14 Aug 2026 SCHEDULE 13G/A
13 Aug 2026 8-K: Results of Operations and Financial Condition

Deramiocel Biologics License Application (BLA) under active FDA review

07 Aug 2026 SCHEDULE 13G
03 Aug 2026 SCHEDULE 13G
30 Jul 2026 8-K: Other Events

SAN DIEGO, July 30, 2026 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that the U.S. Food and Drug Admini...

29 Jul 2026 8-K: Other Events

--Independent Peer Review Provides External Validation of the Trial's Design, Statistical Methodology and Findings--

14 Jul 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

On July 9, 2026, Capricor Therapeutics, Inc. (“Capricor”) entered into a Lease Agreement (the “Lease”) with ARE-SD Region No. 39 Owner, LLC (“Landlord”) for approximately 171,000 rentable square feet located at 9625 Towne Centre Drive, S...

29 Jun 2026 Form 4: Krasney Karen, EVP, GENERAL COUNSEL

Received 24,100 shares by exercise or conversion ($76.6K) · Sold 24,100 shares ($732K)

29 Jun 2026 Form 4: Bergmann Anthony, CHIEF FINANCIAL OFFICER

Received 24,100 shares by exercise or conversion ($76.6K) · Sold 24,100 shares ($732K)

26 Jun 2026 8-K: Other Events

Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

24 Jun 2026 Form 4: Krasney Karen, EVP, GENERAL COUNSEL

Received 500 shares by exercise or conversion ($1.59K) · Sold 500 shares ($15K) · Received 400 shares by exercise or conversion ($1.27K) · 1 more

24 Jun 2026 Form 4: Bergmann Anthony, CHIEF FINANCIAL OFFICER

Received 500 shares by exercise or conversion ($1.59K) · Sold 500 shares ($15K) · Received 400 shares by exercise or conversion ($1.27K) · 1 more

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support